News
Sino Biopharmaceuticals plans to pay up to nearly $951 million to acquire LaNova Medicines, which previously licensed drugs ...
Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback